Continue Reading
Full article on Unknown
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Market Intelligence Analysis
AI-Powered
Why This Matters
Foghorn Therapeutics has closed a $50 million registered direct financing at a 30% premium, selling 2.03 million shares of common stock at $6.71 per share. This financing is expected to provide the company with additional capital to support its research and development efforts. The premium at which the financing was closed indicates strong investor interest in the company.
Market Impact
Market impact analysis based on bullish sentiment with 90% confidence.
Sentiment
Bullish
AI Confidence
90%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered direct financing at a 30% premium. The registered direct offering included the sale of 2,030,314 shares of common stock at $6.71 per share (issue price). Certain investors received pre-funded warrants to
Original article published by
Unknown
on January 14, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.